These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16353164)

  • 1. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London?
    Schneider LS
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):9-13. PubMed ID: 16353164
    [No Abstract]   [Full Text] [Related]  

  • 2. People with Alzheimer's disease are denied drugs.
    Scott H
    Br J Nurs; 2000 Nov 9-22; 9(20):2120. PubMed ID: 12271179
    [No Abstract]   [Full Text] [Related]  

  • 3. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Bosanquet N; Yeates A
    Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908
    [No Abstract]   [Full Text] [Related]  

  • 4. NICE vindicated in UK's High Court.
    Horton R
    Lancet; 2007 Aug; 370(9587):547-8. PubMed ID: 17707735
    [No Abstract]   [Full Text] [Related]  

  • 5. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease.
    Ballard C; Corbett A; Sharp S
    Expert Rev Neurother; 2011 Mar; 11(3):327-9. PubMed ID: 21375436
    [No Abstract]   [Full Text] [Related]  

  • 6. NICE to see the bigger picture.
    Lancet Neurol; 2006 Feb; 5(2):103. PubMed ID: 16426980
    [No Abstract]   [Full Text] [Related]  

  • 7. Counting costs. Patients will suffer from limits on Alzheimer's drugs.
    Page S
    Nurs Stand; 2005 May 25-31; 19(37):24-5. PubMed ID: 15938410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 9. The treatment of mild Alzheimer's disease post-NICE.
    Connelly PJ; Passmore AP; Lawlor BA
    Int J Geriatr Psychiatry; 2007 Dec; 22(12):1262-3. PubMed ID: 17503543
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The costs of Alzheimer's disease treatment: the rationale of acetylcholinesterase inhibitors use?].
    Sobów TM; Kłoszewska I
    Psychiatr Pol; 1999; 33(5):761-7. PubMed ID: 10761441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-dementia drugs.
    Allen H
    Int J Geriatr Psychiatry; 1999 Apr; 14(4):239-43. PubMed ID: 10340181
    [No Abstract]   [Full Text] [Related]  

  • 13. NICE recommends drugs for moderate Alzheimer's disease.
    Mayor S
    BMJ; 2006 Jan; 332(7535):195. PubMed ID: 16439382
    [No Abstract]   [Full Text] [Related]  

  • 14. NICE proposes to withdraw Alzheimer's drugs from NHS.
    Kmietowicz Z
    BMJ; 2005 Mar; 330(7490):495. PubMed ID: 15746112
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with mild Alzheimer's disease should have access to drugs, says draft NICE guidance.
    Kmietowicz Z
    BMJ; 2010 Oct; 341():c5562. PubMed ID: 20926475
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tacrine and "profitability"].
    Nygaard HA
    Tidsskr Nor Laegeforen; 1997 Feb; 117(5):726. PubMed ID: 9102968
    [No Abstract]   [Full Text] [Related]  

  • 18. Ten years of cholinesterase inhibitors.
    Rodda J; Walker Z
    Int J Geriatr Psychiatry; 2009 May; 24(5):437-42. PubMed ID: 19367617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England.
    Purandare N; Swarbrick C; Fischer A; Burns A
    Int J Geriatr Psychiatry; 2006 Oct; 21(10):961-4. PubMed ID: 16927408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.